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According to traditional Chinese medicine theories, Euphorbiae Pekinensis Radix and
Glycyrrhizae Radix should not be used together in one prescription, because their
interaction leads to an unexpected consequence. However, the mechanism remains
unclear. The purpose of this study was to ﬁnd out whether CYP2C9 was involved in
this herb–herb interaction by using tolbutamide as a probe substrate in vivo and in vitro.
Both Euphorbiae Pekinensis Radix and Glycyrrhizae Radix showed induction activity toward
CYP2C9, while the combination of them showed a more potent induction activity toward
CYP2C9 in vivo. In vitro study revealed only the combination of the herbs could induce
the activity of CYP2C9. Thus, both in vivo and in vitro study indicated combination of
Glycyrrhizae Radix and Euphorbiae Pekinensis Radix could induce the activity of CYP2C9
to a high level, which may result in decreased plasma levels of major active ingredients of
these two herbs, as well as other herbs in the prescriptions. Further research also appears
to be necessary to identify the main enzymes involved in the metabolism of the active
ingredients in Glycyrrhizae Radix and Euphorbiae Pekinensis Radix.
Keywords: Glycyrrhizae Radix, Euphorbiae Pekinensis Radix, CYP2C9, herb–herb interaction, traditional Chinese
medicine
INTRODUCTION
Euphorbiae Pekinensis Radix is the dried roots of Euphorbia
pekinensis (EP) Rupr., which belongs to the Euphorbiaceae family
(Tao et al., 2013a). Pharmacological investigations demonstrated
that its extract exhibited a variety of biological effects, includ-
ing possess cytotoxic, antivirus, and anti-inﬂammatory activity
(Mucsi et al., 2001; Corea et al., 2004; Hou et al., 2013). However,
it is considered as a toxic herb in Chinese medicine. Glycyrrhizae
Radix, the root of Glycyrrhiza uralensis (GU) Fisch., or G. glabra
L., or G. inﬂata Bat., Leguminosae, is one of the oldest and
most popular herbal medicines in the world, and it is recorded
in the pharmacopeias of many Asian and European countries,
including China, Japan, and the UK (Tao et al., 2013b). Exten-
sively used in traditional Chinese medicine (TCM), it appears as
a component herb in approximately 60% of all TCM prescrip-
tions (Zhang and Ye, 2009) because most TCM practitioners in
ancient and modern times commonly believe that Glycyrrhizae
Radix may harmonize and modify other herbs (Shen et al., 2013).
However, according to TCM theories, Euphorbiae Pekinensis and
Glycyrrhizae Radix are prohibited to be used together in TCM
clinics, which has been recorded in each edition of Chinese Phar-
macopeia (Commission, 2010). From the previous reports, the
side effects of this herb–herb interaction might be classiﬁed into
three types including acute andpredictable reactions, idiosyncratic
reactions and cumulative, chronic, or delayed toxicity (Lee et al.,
2013). Until now, the mechanism of this herb–herb interaction
remains unclear.
A number of studies have reported many herbal interactions
due to cytochrome P-450 enzymes (CYP450) which can mediate
drug elimination as a major mechanism responsible for such types
of interactions. CYP450 constitute a large family of cysteinato-
heme enzymes, and are present in all forms of life (plants,
bacteria, and mammals; Meunier et al., 2004). These enzymes
are potent oxidants that are able to catalyze the hydroxylation
of saturated carbon hydrogen bonds, the epoxidation of dou-
ble bonds, the oxidation of heteroatoms, dealkylation reactions,
oxidations of aromatics, and so on (Meunier et al., 2004), thus
play a key role in the oxidative transformation of numerous
endogenous compounds as well as xenobiotics including drugs
(de Montellano and De Voss, 2002). They are well known to be
composed of more than 400 isoforms. Among them, CYP2C9 has
been considered as one of the most important drug-metabolizing
enzymes subtypes in human, which is vital for the hydroxyla-
tion of 10–20% of commonly prescribed drugs (Al-Jenoobi, 2010;
Yu et al., 2014). According to previous reports, CYP2C9 catalytic
activities can be inducted or inhibited by many drugs, as well
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as TCM, thus giving rise to drug–drug interactions (Schmidt
et al., 2007) and drug–herb interactions (Kennedy and Seely,
2010).
In the previous reports, there is a lack of information about
the potential interactions of herbs, not to mention the limited
availability of herb–herb interaction studies involving CYP2C9.
The aim of this study was to investigate the potential mechanism
of the incompatibility of Euphorbiae Pekinensis and Glycyrrhizae
Radix from the ﬁeld of drug-metabolizing enzymes CYP2C9.
MATERIALS AND METHODS
CHEMICALS AND REAGENTS
Tolbutamide, 4-hydroxytolbutamide, chlorpropamide, glucose
6-phosphate (G 6-P), glucose 6-phosphate dehydrogenase (G 6-
PDH, Type V), and nicotinamide adenine dinucleotide phosphate
(NADP) were purchased from Sigma Chemical Co. (St Louis, MO,
USA). Acetonitrile (HPLC grade) was purchased from TEDIA
Company Inc. (Fairﬁeld, USA); formic acid was obtained from
Merck KGaA (Darmstadt, Germany); ultra-pure water was puri-
ﬁed by an EPED super puriﬁcation system (Nanjing, China). The
distilled water was used for the extraction and preparation of
samples. Other reagents and chemicals were of analytical grade.
MATERIALS AND EXTRACT PREPARATION
The dried roots of EP were collected in May 2010 from Nanning
City, Guangxi province, China, and the dried roots and rhizomes
of GUwere collected inDecember 2010 fromLingwuCity,Ningxia
Province,China. The twoherbswere identiﬁed byProfessorChun-
gen Wang (Department of Pharmacognosy, College of Pharmacy,
Nanjing University of Chinese Medicine, Nanjing, China).
The dry herb pieces of EP (500 g) and GU (500 g) were mixed,
and then extracted with boiling water (1:10, w:v) for twice, 2 h for
each time, ﬁltered through gauze. The two ﬁltrates were merged
and evaporated by rotary evaporation under vacuum at 60◦C, thus
the water extract of EP (WEP)-GU (WEP-GU) were obtained.
Its concentration was set at 2 g/mL (2 g crude herbs per 1 mL)
using pure water. The single dry herb pieces of EP (500 g) and
GU (500 g) were extracted through the same procedure, and then
1 g/mL WEP and GU (WGU) were obtained, respectively. Addi-
tionally, the dry herb pieces of EP (500 g) were reﬂuxed with
90% ethanol under the same extract conditions as WEP-GU. The
resulting extract was evaporated to dryness under reduced pres-
sure, and was diluted in distilled H2O. Finally, 1 g/mL alcohol
extract of EP (AEP) were prepared. All prepared solutions were
stored at 4◦C.
ANIMALS AND HERBS ADMINISTRATION
Seventy two normal male Sprague–Dawley rats (SPF) weighing
200–250 g were purchased from Shanghai Slac Laboratory Ani-
mal Co. Ltd. (Shanghai, China). The rats were housed in a room
with controlled conditions (temperature 20–25◦C, relative humid-
ity 55–60% and 12 h dark–light cycle), and allowed to freely access
to food and water for 7 days acclimation. Animal study was carried
out in accordance with the Guideline for Animal Experimentation
of Nanjing University of Chinese Medicine, and the protocol was
approved by the Animal Ethics Committee of the institution. All
efforts were made to ameliorate suffering of animals.
The rats were randomly divided into six groups with 12 rats in
each: Control,WEP,WGU,WEP-GU,AEP, andAEP-WGU groups.
The rats inWEP,WGU, andAEP groups were intragastrically given
WEP,WGU, andAEP extracts at a dose of 10 g/kg (10 g crude herbs
per 1 kg rat body weight). WEP-GU group were oral administra-
tion of WEP-GU at a dosage of 20 g/kg, andAEP-WGU group were
given the mixed solutions of WGU (10 g/kg) and AEP (10 g/kg).
The animal dose of WEP, WGU, WEP-GU, AEP, and AEP-WGU
extracts was extrapolated from the human daily dose, according
to human dosage in clinical practice and human–rat coefﬁcient of
skin surface area. The dose of WGU,WEP extracts were equivalent
to ten and ﬁfty times of the adult daily dose crude herbs based on
the TCM prescription, respectively. Control group was intragas-
trically given the same volume of saline solution. All animals were
administered by oral gavage one time each day for continuous
10 days and fasted for 12 h before the experiments.
BLOOD SAMPLING
For 6 rats of each group, tolbutamide was injected via caudal vein
at a dose of 10 mg/kg 24 h after the last treatment of herbal extracts
and blood samples (about 400 μL) were immediately collected in
heparinized 1.5 mL polythene tubes from the suborbital vein at
0.167, 0.333, 0.667, 1.5, 4.0, 3.5, 4.0, 6.0, 8.0, and 22 h after
injection. Within 30 min after blood withdrawal, the samples were
centrifuged at 5000 rpm for 10 min and the separated plasma
samples were stored at −80◦C prior to analysis.
PREPARATION OF PLASMA SAMPLES
A simple liquid–liquid extraction method was followed for extrac-
tion of tolbutamide and 4-hydroxytolbutamide. A 200 μL volume
of plasma sample was transferred to a 1.5 mL PE tube, 50μL inter-
nal standard solution (chlorpropamide dissolved in methanol at a
concentration of 30 μg/mL) was spiked and vortexed for 1 min,
followed by adding 1.0 mL absolute ether. After vortexing for
1.0 min, samples were centrifuged at 13,000 rpm for 10 min. The
super layer was transferred to a 1.5 mL PE tube and evaporated
to dryness at 30◦C under a slight stream of nitrogen. The residue
was reconstituted in 120 μL of methanol and vortex mixed for
3min, followedby centrifugation at 13,000 rpm for 10min. Finally,
a 10 μL aliquot of the supernatant was injected for HPLC–UV
analysis.
MICROSOMES PREPARATION
The other six rats of each group were sacriﬁced 12 h after the last
treatment and the livers were immediately removed, weighed, and
washed in cold phosphate buffer saline (50mMTris–HCl, 150mM
KCl, 2 mM EDTA, pH 7.4). The liver was then homogenized in
3 mL buffer per gram of liver. The homogenates were submit-
ted to several differential centrifugations, as previously described
(Richert et al., 2002). Microsomal samples were ﬁnally aliquoted
and frozen at −80◦C until analysis. Protein content was deter-
mined by the method of Bradford (Bradford, 1976), and BSA was
used as a standard.
MICROSOMAL INCUBATION
The incubation mixture (ﬁnal volume: 200 μL) consisted of
an NADPH-generating system (0.5 mM NADP, 5.0 mM G-6-P,
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1.0 U/mL G-6-P-OH, 5.0 mM MgCl2), 0.1 M phosphate buffer
(pH 7.4), 0.5 mg/mL rat liver microsomes and 100 μM tolbu-
tamide. After a 5 min pre-incubation at 37◦C, the reaction
was initiated by adding NADP. The reaction was terminated by
adding 200 μL cold acetonitrile (containing internal standard
chlorpropamide, 100 ng/mL) and placing the tubes on ice after
incubation at 37◦C for 50 min. Preliminary experiments showed
that the formation of 4-hydroxytolbutamide was linear against
incubation time for up to 60 min for 0.5 mg/mL of rat hepatic
microsomes.
PREPARATION OF MICROSOMAL SAMPLES
Microsomal samples were centrifuged at 13,000 rpm for 10 min
and a 10 μL aliquot of the supernatant was injected for UPLC–
MS/MS analysis.
ANALYSIS OF BLOOD SAMPLE
Analysis of blood sample was performed using a Waters 2695
Alliance HPLC system (Waters Corporation, Milford, MA, USA),
consisting of a quaternary pump solvent management system,
an on-line degasser, and an autosampler. The raw data were
detected by 2998 PDA, acquired, and processed with EmpowerTM
Software. An Agilent Extend-C18 column (4.6 mm × 150 mm,
5 μm) was applied and detection wavelength was set at 220 nm
for all analyses. The mobile phase was composed of A (water)
and B (acetonitrile) with a linear gradient elution: 0–8 min,
15–35% B; 8–10 min, 35% B; 10–10.5 min, 35–15% B; and
10.5–13.5 min, 15% B. The ﬂow rate of the mobile phase was
1.0 mL/min, and the column temperature was maintained at
30◦C.
ANALYSIS OF MICROSOMAL SAMPLE
Analysis of microsomal sample was performed using a Waters
ACQUITY UPLC system (Waters, Milford, MA,USA). An Acquity
BEH C18 column (2.1 mm × 100 mm, 1.7 μm) maintained at
30◦C was used with an injection volume of 2 μL. Mobile phase A
was a 0.1% formic acid/water solution (1/1000, v/v), mobile phase
B was a acetonitrile solution, and the ﬂow rate was 0.4 mL/min.
The linear gradient conditions were: 0–2 min, 30–90% B; 2–
2.5 min, 90% B; 2.5–3.0 min, 90–30% B; and 3.0–3.5 min,
30% B.
Mass spectrometric analysis was carried out using a Waters
Xevo TQ tandem quadrupole mass spectrometer (Micromass MS
Technologies, Manchester, UK). All of the target compounds
were detected using an ESI ion source. The parameters in the
source were set as follows: capillary voltage = 3.0 kV; source
temperature = 150◦C; desolvation temperature = 550◦C; cone
gas ﬂow = 50 L/h, and desolvation gas ﬂow = 1000 L/h.
Quantiﬁcation was performed using multiple reaction moni-
toring (MRM) of the transitions m/z 270.58 → 73.97, m/z
287.16 → 73.97, and m/z 275.03 → 125.86 for tolbu-
tamide, 4-hydroxytolbutamide, and IS, respectively. All data
were acquired and processed using the Masslynx 4.1 soft-
ware.
The method was validated in terms of speciﬁcity, lower limit
of quantiﬁcation (LLOQ), linearity, accuracy, precision, recov-
ery, matrix effect, and stability, in according with the currently
accepted USA Food and Drug Administration (FDA) bioana-
lytical method validation guidelines and the subsequent 2006
Bio-analytical Methods Validation Workshop white paper.
STATISTICAL ANALYSIS
The corresponding pharmacokinetic parameters were calculated
by the software of DAS 2.0 (Pharmacology Institute of China).
Data were expressed as mean ± SD. ANOVA was used as statistical
methods to evaluate the effects of the different treatment.
RESULTS
VALIDATION OF THE ANALYTICAL APPROACH
Under the conditions described in the experimental section, the
validated HPLC–UV method and UPLC–MS/MS method were
used todetermine the levels of theprobe substrate (tolbutamide for
CYP2C9) and its metabolites in rat plasma and in the incubation
system after different treatment for 10 days, respectively.
Standard curves of tolbutamide and 4-hydroxytolbutamide
in rat plasma were established over the concentration range of
97.65–50,000 ng/mL and 97.65–6250 ng/mL, respectively. The cal-
ibration curves were: y = 0.097x + 0.021 (r2 = 0.9991, n = 5) for
tolbutamide and y = 0.072x + 0.001 (r2 = 0.999, n = 5) for 4-
hydroxytolbutamide (y = concentration of the analyte; x = peak
area ratio of each analyte versus internal standard).
Standard curves of 4-hydroxytolbutamide in the incubation
system was established over the concentration range of 1–
10,000 ng/mL and the calibration curveswere:Y = 4.147X + 0.150
(r2 = 0.999, n = 5; Y = concentration of 4-hydroxytolbutamide;
X = peak area ratio of 4-hydroxytolbutamide versus internal
standard).
The results of linear regression analysis showed that the cor-
relation coefﬁcients of the calibration curves for all sample types
were above 0.996. The limit of quantiﬁcations of tolbutamide and
4-hydroxytolbutamide in rat plasma were both 97.65 ng/mL, and
that of 4-hydroxytolbutamide in incubation system were 1 ng/mL.
The precision and accuracy of intra-day and inter-day of all the
analyte for the low-, medium-, and high-quality control samples
were below 15%. The result of the chromatographic validation
showed that the assay methods were suitable for this study.
RESULT OF IN VIVO EXPERIMENT
Pharmacokinetic proﬁles of tolbutamide after different treatment
were used to describe the activity of CYP2C9. Mean plasma con-
centration time curves of tolbutamide in different groups are
presented in Figure 1, which revealed that the clearance of tolbu-
tamide in other treatment group were faster than Control. The
effects of different treatment on pharmacokinetic parameters of
tolbutamide in rats are presented in Table 1.
Compared with Control, the pharmacokinetic parameters
(AUC0−1320 min, AUC0−∞, MRT0−1320 min, MRT0−∞ and t1/2)
of tolbutamide showed no signiﬁcant change in WGU, which
showed that GU had no inductive or inhibitory effect on the
activities of CYP2C9 after multiple oral administrations in rats.
Compared with Control, the AUC0−∞ of WEP and AEP signiﬁ-
cantly decreased (P < 0.05), AUC0−1320 min of AEP signiﬁcantly
decreased (P < 0.05). The result showed that CYP2C9 activ-
ity was signiﬁcantly induced by single use of EP. MRT0−∞ and
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FIGURE 1 | Mean plasma concentration–time curve of tolbutamide after treatment. (A) Control andWEP; (B) Control andWEP-GU; (C) Control and AEP;
(D) Control and AEP-WGU; (E) Control andWGU; (x¯± s, n = 6).
Table 1 | Main pharmacokinetic parameters of tolbutamide in rats (x¯± s, n = 6).
Parameters Control WGU WEP AEP WEP-GU AEP-WGU
AUC0−1320 min/μg min mL−1 16871.8 ± 1425.6 15614.6 ± 1823.8 15212.0 ± 1686.5 15023.3 ± 1092.1∗ 13172.8 ± 1768.8∗∗# 14603.0 ± 1274.4∗
AUC0−∞/μg min mL−1 24602.7 ± 3360.0 21899.7 ± 3919.3 19740.3 ± 2421.8∗ 20867.1 ± 1139.6∗ 16513.1 ± 2679.7∗∗∗ 17910.5 ± 2896.9∗∗
t1/2/min 275.6 ± 66.1 271.2 ± 44.2 231.1 ± 28.4 268.7 ± 26.0 212.4 ± 17.8∗ 196.7 ± 43.2∗♦
MRT0−1320 min/min 179.0 ± 17.8 181.1 ± 7.9 180.1 ± 5.3 181.7 ± 7.5 170.7 ± 5.9# 167.9 ± 9.6♦
MRT0−∞/min 404.3 ± 81.3 394.6 ± 60.0 372.0 ± 48.7 380.0 ± 42.0 299.0 ± 23.8∗## 297.6 ± 52.6∗♦
Vz/L kg−1 0.32 ± 0.04 0.36 ± 0.26 0.34 ± 0.04 0.37 ± 0.04 0.38 ± 0.04 0.32 ± 0.02♦
CLz/L min−1 kg−1 0.001 0.001 0.001 0.001 0.001 0.001
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared with Control group.
#P < 0.05, ##P < 0.01 compared withWEP group.
♦P < 0.05 compared with AEP group.
P < 0.05,  P < 0.01 compared withWGU group.
t1/2 of WEP-GU decreased and had a very signiﬁcant differ-
ence (P < 0.01) compared with Control, AUC0−∞ decreased
and had a extremely signiﬁcant difference (P < 0.001) compared
with Control. It revealed that the co-decoction of EP and GU
could induce the activity of CYP2C9. The t1/2 and MRT0−∞ of
AEP-WGU all decreased signiﬁcantly (P < 0.05), AUC0−1320 min
decreased very signiﬁcantly (P < 0.01), AUC0−∞ decreased
extremely signiﬁcantly (P < 0.001) compared with Control, which
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showed that the co-administration of AEP and WGU could also
induce the activity of CYP2C9. Therefore,WGUhad no signiﬁcant
effect on the activity of CYP2C9. BothWEP andAEP could induce
the activity of CYP2C9, and both the co-decoction of EP and GU
and co-administration of AEP and WGU could also induce the
activity of CYP2C9.
Compared with WEP, AUC0−1320 min and MRT0−1320 min of
WEP-GU decreased very signiﬁcantly (P < 0.01) and MRT0−∞
decreased extremely signiﬁcantly (P < 0.001). Compared with
WGU, t1/2, MRT0−1320 min and MRT0−∞ of WEP-GU decreased
signiﬁcantly (P < 0.05). It showed that the co-decoction of
EP and GU had a more potent inductive effect on the activ-
ity of CYP2C9 than single decoction solution of EP or GU.
Compared with AEP, t1/2, MRT0−1320 min and MRT0−∞ of
AEP-WGU decreased signiﬁcantly (P < 0.05). Compared with
WGU, AUC0−1320 min, AUC0−∞, MRT0−1320 min, and t1/2 of
AEP-WGU decreased signiﬁcantly and MRT0−∞ decreased very
signiﬁcantly (P < 0.01). It showed that the co-administration
of AEP and WGU had a more potent inductive effect on
the activity of CYP2C9 than single administration of AEP
or WGU.
Mean plasma concentration time curves of 4-hydroxytolbuta-
mide in different groups are presented in Figure 2. The effects
of different treatment on pharmacokinetic parameters of 4-
hydroxytolbutamide in rats are presented in Table 2.
Compared with Control, the AUC0−∞ of WGU increased sig-
niﬁcantly (P < 0.05); AUC0−1320 min and AUC0−∞ of WEP
increased signiﬁcantly (P <0.05); andAUC0−1320 min of WEP-GU
and AEP-WGU increased signiﬁcantly (P < 0.05), which revealed
that all the treatment could induce the activity of CYP2C9 to some
extent.
RESULT OF IN VITRO EXPERIMENT
After microsomal incubation, the formation of 4-hydroxytolbut-
amide were determined and thus the formation rate of 4-
hydroxytolbutamide of different treatment group were calculated
and used as the indicator of the activity of CYP2C9 in vitro, as
was presented in Figure 3. Compared to Control (0.137 ± 0.030),
FIGURE 2 | Mean plasma concentration–time curve of 4-hydroxytolbutamide after treatment. (A) Control andWEP; (B) Control andWEP-GU; (C) Control
and AEP; (D) Control and AEP-WGU; (E) Control andWGU; (x¯± s, n = 6).
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Table 2 | Main pharmacokinetic parameters of 4-hydroxy tolbutamide in rats (x¯± s, n = 6).
Parameters Control WGU WEP AEP WEP-GU AEP-WGU
AUC0−1320 min/μg min mL−1 488.3 ± 91.1 602.4 ± 69.5 634.1 ± 27.8∗ 580.3 ± 135.2 628.5 ± 35.1∗ 683.1 ± 167.7∗
AUC0−∞/μg min mL−1 506.9 ± 85.7 667.0 ± 125.7∗ 687.5 ± 75.0∗ 651.9 ± 168.9 715.9 ± 113.4∗∗ 811.0 ± 199.9∗∗
t1/2/min 243.3 ± 62.7 372.0 ± 159.3 343.6 ± 150.4 373.2 ± 161.1 390.6 ± 215.2 524.8 ± 339.3
MRT0−1320 min/min 340.7 ± 133.0 367.0 ± 42.9 439.2 ± 76.9 340.8 ± 93.2 387.7 ± 41.6 421.8 ± 59.1
MRT0−∞/min 476.3 ± 260.2 527.4 ± 141.5 654.7 ± 152.4 490.1 ± 185.1 599.1 ± 171.3 770.2 ± 324.3
Vz/L kg−1 6.9 ± 1.5 7.75 ± 2.14 7.04 ± 2.43 7.86 ± 1.98 7.45 ± 3.35 9.2 ± 5.3
CLz/L min−1 kg−1 0.020 ± 0.004 0.016 ± 0.003 0.015 ± 0.001 0.017 ± 0.006 0.013 ± 0.004∗ 0.013 ± 0.003
∗P < 0.05, ∗∗P < 0.01 compared with Control group.
FIGURE 3 | Activities of CYP 2C9 in liver microsomes (x¯± s, n = 6).∗P < 0.05 compared with control.
the formation rate (nmol/min mgpro) of WGU (0.156 ± 0.022),
WEP (0.173 ± 0.018), and AEP (0.165 ± 0.019) had the tendency
of promotion, but there was no statistically signiﬁcant differ-
ence. WEP-GU (0.187 ± 0.031) and AEP-WGU (0.184 ± 0.033)
increased signiﬁcantly (P < 0.05), which revealed the correspond-
ing treatment could induce the activity of CYP2C9.
DISCUSSION
CYP2C9 is an enzyme of the CYP450 superfamily of monooxyge-
nases (Johnson et al., 2005). Some other isoforms of CYP enzymes,
such as CYP3A4, CYP2D6, and CYP2C19, play important roles in
drug metabolism (Zanger and Schwab, 2013) as well, but accu-
mulating evidence indicates that CYP2C9 ranks amongst the most
important drug metabolizing enzymes in human (Miners and Bir-
kett, 1998), so we chose the single isoform of metabolic enzymes
(CYP2C9) to study the herb–herb interaction of Glycyrrhizae
Radix and Euphorbiae Pekinensis Radix. Substrates for CYP2C9
includeﬂuoxetine, losartan, phenytoin, tolbutamide, torsemide, S-
warfarin, and numerous non-steroidal anti-inﬂammatory drugs
(NSAIDs) (Leemann et al., 1993; Takahashi and Echizen, 2001;
Zhou et al., 2010). In human tolbutamide is metabolized almost
exclusively along a single pathway. Methylhydroxylation to form
4-hydroxytolbutamide is the initial and rate-limiting step; subse-
quent oxidation of dehydrogenases produces carboxytolbutamide
(Nelson and O’Reilly, 1961; Thomas and Ikeda, 1966). Overall,
this pathway accounts for up to 85% of tolbutamide clearance in
human (Thomas and Ikeda, 1966; Veronese et al., 1990). There
is overwhelming evidence that CYP2C9 is solely responsible for
the hydroxylation of tolbutamide. Some isoforms of CYP2C
have high relevance with CYP2C9, according to the literature
(Lasker et al., 1998), both CYP2C9 and CYP2C19 were efﬁcient
tolbutamide hydroxylases, but the microsomal CYP2C19 levels
were substantially less than CYP2C9 levels which suggested that
the former P450 played a nominal role in hepatic tolbutamide
metabolism, thus tolbutamide was widely accepted as a probe sub-
strate for assessment of hepatic CYP2C9 activity, both in vitro and
in vivo.
In this study, the classics probe substrate tolbutamide was used
to evaluate the effect of single Euphorbiae Pekinensis Radix, single
Glycyrrhizae Radix, and the combination of both on the activity
of CYP2C9. According to TCM (Commission, 2010), Glycyrrhizae
Radix is used in form of water decoction and Euphorbiae Pekinen-
sis Radix is used in form of water decoction, pill, and powder.
Thus water extract of Glycyrrhizae Radix, both water extract and
alcohol extract of Euphorbiae Pekinensis Radix were prepared for
this research. The combination of both herbs was prepared by (1)
water extract of the mixed Euphorbiae Pekinensis Radix and Gly-
cyrrhizae Radix (1:1, co-decoction); (2) mixture of water extract
of Glycyrrhizae Radix and alcohol extract of Euphorbiae Pekinen-
sis Radix (1:1, co-administrated). In vivo study demonstrated that
Glycyrrhizae Radix (water extract), Euphorbiae Pekinensis Radix
(both water extract and alcohol extract), and combination of two
herbs (both co-decoction and co-administrated) could induce the
activity of CYP2C9. Compared to single herb, combination of
Glycyrrhizae Radix and Euphorbiae Pekinensis Radix had a more
potent induction effect on the activity of CYP2C9. In vitro study
revealed that single herb showed no statistically signiﬁcant effects
on the activity of CYP2C9, while the combination of both herbs
could induce the activity of CYP2C9. In general, both in vivo
and in vitro study indicated that the combination of Glycyrrhizae
Radix and Euphorbiae Pekinensis Radix could induce the activity
of CYP2C9 to a high level.
According to drug–drug interaction based on CYP450, inhi-
bition of CYPs can lead to increased plasma levels of drugs that
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are substrates for CYPs and thus can cause toxicity. In contrast,
induction of this enzyme can result in decreased plasma levels
of these drugs and consequently reduce their efﬁcacy (Guo et al.,
2014). As CYP2C9 was an important drug-metabolizing enzyme,
the induction effect of combination of Glycyrrhizae Radix and
Euphorbiae Pekinensis Radix on activity of CYP2C9 may speed
up the metabolism of major active ingredients in Glycyrrhizae
Radix and Euphorbiae Pekinensis Radix, as well as other herbs in
the prescriptions, thus lower the plasma concentration of the these
active ingredients and also the concentration of the ingredients at
the target site, resulting in a poor efﬁcacy. To further elucidate that,
the enzymes involved in the metabolism of the active ingredients
in Glycyrrhizae Radix and Euphorbiae Pekinensis Radix needs to
be studied.
Moreover, the involvement of CYP2C9 has been shown in
the activation of several carcinogens, such as polycyclic aromatic
hydrocarbons and heterocyclic aromatic amines (García-Martín
et al., 2002). Beside the well-known role in metabolizing and acti-
vating of pro-carcinogens, CYP2C9 seems to be relevant for early
esophageal cancer development by promoting tumor cell prolif-
eration (Schmelzle et al., 2011) and altered CYP2C9 metabolism
may play a relevant role in lung carcinogenesis (García-Martín
et al., 2002). The induction of CYP2C9 activity by combination of
Glycyrrhizae Radix and Euphorbiae Pekinensis Radix may lead to
a high risk for cancer.
CONCLUSION
It was concluded that the combination of Glycyrrhizae Radix and
Euphorbiae Pekinensis Radix were capable of signiﬁcantly induc-
ing CYP2C9 metabolic activity in vitro and in vivo. If the major
active ingredients in Glycyrrhizae Radix and Euphorbiae Pekinen-
sis Radix are mainly metabolized by CYP2C9, it will result in a
poor efﬁcacy. Moreover, these two herbs therefore, might have the
potential to interact with other conventional medicines metab-
olized and eliminated from the body by CYP2C9. Although we
are aware that our results are somewhat preliminary, they indi-
cate at least a mechanism of herb–herb interaction of Euphorbiae
Pekinensis Radix and Glycyrrhizae Radix.
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